UNICA IRIS Institutional Research Information System

MULAS, OLGA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 344.304
NA - Nord America 3.864
AS - Asia 2.693
SA - Sud America 469
AF - Africa 96
OC - Oceania 10
Totale 351.436
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 341.197
US - Stati Uniti d'America 3.749
NL - Olanda 1.906
SG - Singapore 1.069
CN - Cina 740
BR - Brasile 341
SE - Svezia 325
VN - Vietnam 261
FI - Finlandia 210
DE - Germania 188
HK - Hong Kong 120
FR - Francia 113
KR - Corea 112
GB - Regno Unito 110
IN - India 88
CA - Canada 66
UA - Ucraina 61
AR - Argentina 52
BD - Bangladesh 42
AT - Austria 40
PL - Polonia 37
JP - Giappone 35
MX - Messico 34
ZA - Sudafrica 33
IQ - Iraq 32
RU - Federazione Russa 22
SA - Arabia Saudita 22
TR - Turchia 22
EC - Ecuador 20
MA - Marocco 18
ES - Italia 17
IR - Iran 17
PK - Pakistan 17
VE - Venezuela 15
CZ - Repubblica Ceca 13
ID - Indonesia 13
PH - Filippine 12
MY - Malesia 11
AE - Emirati Arabi Uniti 10
ET - Etiopia 10
UZ - Uzbekistan 10
AU - Australia 8
BE - Belgio 8
BO - Bolivia 8
CO - Colombia 8
EG - Egitto 8
IE - Irlanda 8
JO - Giordania 8
LT - Lituania 8
UY - Uruguay 8
CL - Cile 7
IL - Israele 7
KZ - Kazakistan 6
OM - Oman 6
TH - Thailandia 6
TN - Tunisia 6
LB - Libano 5
PE - Perù 5
RO - Romania 5
AZ - Azerbaigian 4
BY - Bielorussia 4
PY - Paraguay 4
RS - Serbia 4
TW - Taiwan 4
CH - Svizzera 3
DZ - Algeria 3
HU - Ungheria 3
JM - Giamaica 3
KE - Kenya 3
NP - Nepal 3
PA - Panama 3
PR - Porto Rico 3
PT - Portogallo 3
AL - Albania 2
BG - Bulgaria 2
CI - Costa d'Avorio 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
KG - Kirghizistan 2
KW - Kuwait 2
LV - Lettonia 2
LY - Libia 2
NG - Nigeria 2
NZ - Nuova Zelanda 2
PS - Palestinian Territory 2
QA - Qatar 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BF - Burkina Faso 1
BW - Botswana 1
CR - Costa Rica 1
CY - Cipro 1
EE - Estonia 1
GR - Grecia 1
GY - Guiana 1
HN - Honduras 1
HR - Croazia 1
IS - Islanda 1
Totale 351.424
Salva come PNG Salva come JPEG
Città #
Cagliari 318.592
Uta 21.912
Amsterdam 1.869
Singapore 562
Ashburn 553
Dallas 312
San Jose 265
Fairfield 232
Boardman 208
Helsinki 172
Beijing 149
Los Angeles 145
Nyköping 145
New York 142
Woodbridge 134
Chandler 123
Houston 118
Seattle 117
Hong Kong 110
Cambridge 102
Wilmington 93
Council Bluffs 86
Shanghai 86
Ho Chi Minh City 81
Santa Clara 81
Hefei 77
Seoul 76
Rome 66
Ann Arbor 64
Milan 62
Lauterbourg 56
Hanoi 53
The Dalles 53
Munich 39
Boston 33
Incheon 33
São Paulo 33
Tokyo 33
Buffalo 30
Frankfurt am Main 28
Orem 28
Warsaw 28
Atlanta 27
London 25
Nuremberg 25
Chicago 24
Toronto 23
Dearborn 21
Redondo Beach 21
San Diego 21
Vienna 21
Denver 20
Jacksonville 20
Montreal 20
Rio de Janeiro 20
Johannesburg 19
Guangzhou 18
Lappeenranta 17
Brooklyn 16
Dong Ket 16
Turku 16
Chennai 15
Redwood City 15
Bologna 14
Da Nang 14
Düsseldorf 13
Mumbai 13
Nanjing 13
Poplar 13
Haiphong 12
Phoenix 12
Baghdad 11
Buenos Aires 11
Krefeld 11
Mexico City 11
Shenzhen 11
Wuhan 11
Jeddah 10
Manchester 10
Paris 10
Addis Ababa 9
Istanbul 9
Pune 9
Stockholm 9
Tashkent 9
Turin 9
Amman 8
Ankara 8
Casablanca 8
Mountain View 8
Naples 8
Porto Alegre 8
Riyadh 8
Tianjin 8
Alghero 7
Belo Horizonte 7
Brasília 7
Brussels 7
Caracas 7
Changsha 7
Totale 347.961
Salva come PNG Salva come JPEG
Nome #
Patient-Physician Communication in Acute Myeloid Leukemia and Myelodysplastic Syndrome 242.317
Infectious Complications in Autoimmune Hemolytic Anemia: A Multi-Center Italian Experience 33.705
Association of Hypometilating Agents (HMA) plus Venetoclax (VEN) in the Treatment of Myeloproliferative Neoplasms in Blastic Phase (MPN-BP) and Acute Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine 3.459
Metabolomics Profile of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors 3.396
Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patients 3.343
Homozygosity for killer immunoglobin-like receptor haplotype A predicts complete molecular response to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia patients 3.307
HLA-G molecules and clinical outcome in Chronic Myeloid Leukemia 3.231
Permanent Discontinuation of Tyrosine Kinase Inhibitor Frontline Therapy in Patients with Chronic Phase Chronic Myeloid Leukemia Patients during the First 36 Months of Treatment: A "Campus CML" Study 2.916
Kir haplotype aa is a possible predictive marker of complete molecular response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia 2.825
Ruolo del trapianto allogenico nelle talassemie 2.768
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart 2.607
Metabolomic Analysis of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors 2.243
Favourable outcome of chronic myeloid leukemia co-expressing e13a2 and e14a2 transcripts, treated with nilotinib 2.191
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis 2.121
Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention 2.116
Rituximab Monotherapy or in Combination with Bendamustine Is Not Inferior to Rituximab-CHOP Regimen in the Treatment of Patients with Splenic Marginal Zone Lymphoma in the Real Life 1.937
Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice 1.875
Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors 1.834
Residual peripheral blood CD26+leukemic stem cells in chronic myeloid leukemia patients during TKI therapy and during treatment-free remission 1.802
Increased incidence of infection in patients with myelofibrosis and transfusion-associated iron overload in the clinical setting 1.676
Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors 1.611
Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib 1.529
Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study 1.496
The association between Major Depressive Disorder and premature death risk in hematologic and solid cancer: a longitudinal cohort study 1.017
Thyroid autoimmunity and hypothyroidism are associated with deep molecular response in patients with chronic myeloid leukemia on tyrosine kinase inhibitors 1.009
Dihydroorotate dehydrogenase inhibition reveals metabolic vulnerability in chronic myeloid leukemia 937
Conditioning Regimens in Patients with β-Thalassemia Who Underwent Hematopoietic Stem Cell Transplantation: A Scoping Review 899
Arterial Hypertension and Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Systematic Review and Meta-Analysis 894
Safety and efficacy of caplacizumab retreatment in a real-life monocentric cohort of patients with immune-mediated thrombotic thrombocytopenic purpura 887
Health-related quality of life profile of patients with immune thrombocytopenia in the real life is impaired by splenectomy 860
Risk and Response-Adapted Treatment in Multiple Myeloma 842
Ruxolitinib does not impair humoral immune response to COVID-19 vaccination with BNT162b2 mRNA COVID-19 vaccine in patients with myelofibrosis 817
Health-Related Quality-of-Life Profile of Pediatric Patients with β Thalassemia after Hematopoietic Stem Cell Transplantation 786
Health-Related Quality of Life Assessment in Patients with Myelodysplastic Syndromes: Evidence from Randomized Clinical Trials 750
Analysis of Early Events during the First Year of Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Phase - Chronic Myeloid Leukemia: A "Campus CML" Study 693
Long-term health-related quality of life in patients with beta-thalassemia after unrelated hematopoietic stem cell transplantation 689
Patients with Chronic Lymphocytic Leukemia Have a Very High Risk of Ineffective Response to the BNT162b2 Vaccine 678
Renin-angiotensin inhibitors reduce thrombotic complications in Essential Thrombocythemia and Polycythemia Vera patients with arterial hypertension 674
Should be a Third Dose of BNT162b2 mRNA COVID-19-Vaccine Administered in Patients with Myelofibrosis Under Ruxolitinib? 667
Chronic graft vs. host disease and hypogammaglobulinemia predict a lower immunological response to the BNT162b2 mRNA COVID-19 vaccine after allogeneic hematopoietic stem cell transplantation 647
The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib 640
Low adherence to therapy and co-morbid depressive episodes are independent determinants of early death in people with cancer 633
Safety and Efficacy of TKIs in very Elderly Patients (≥75 Years) with Chronic Myeloid Leukemia 628
Prognostic Role of Cell Blood Count in Chronic Myeloid Neoplasm and Acute Myeloid Leukemia and Its Possible Implications in Hematopoietic Stem Cell Transplantation 616
CML-164 Dihydroorotate Dehydrogenase Inhibition Reveals Metabolic Vulnerability in Chronic Myeloid Leukemia 615
Adherence to treatment in patients with solid and hematological cancers. Could spiritual and psychological support facilitate optimal adherence? 591
Pathogenic and Prognostic Roles of Paraneoplastic Leukocytosis in Cervical Cancer: Can Genomic-Based Targeted Therapies Have a Role? A Literature Review and an Emblematic Case Report 554
Long-Term Health-Related Quality of Life and Clinical Outcomes in Patients with β-Thalassemia after Splenectomy 532
Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic-phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CML 492
Understanding the user's point of view: when the doctor gets sick with cancer and seeks help 476
Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network 476
Systematic Review and Meta-Analysis of Health-Related Quality of Life in Patients with β-Thalassemia Underwent Hematopoietic Stem Cell Transplantation 450
Extracellular vesicles in the Chronic Myeloid Leukemia scenario: an update about the shuttling of disease markers and therapeutic molecules 448
Pro-Inflammatory and Pro-Oxidative Changes During Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study) 438
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study 434
The Direct and Indirect Effects of Tyrosine Kinase Inhibitors on the Cardiovascular System in Chronic Myeloid Leukemia 421
On the Children Side. Overview of 194 Outcomes from Gimema Registry of Conception/Pregnancy in Chronic Myeloid Leukemia (CML) 417
Patients' Perception of Usability and Utility of a Digital Health Tool for Electronic Patient-Reported Outcomes Monitoring in Real-Life Hematology Practice: Evidence from the Gimema-Alliance Platform 367
Increase of Arterial Stiffness in Patients with Polycythemia Vera 336
Long-term health-related quality of life and mental health in patients with immune thrombotic thrombocytopenic purpura 334
Association of Hypomethylating Agents + Venetoclax in the Real-Life Treatment of Myeloproliferative Neoplasms in Blastic Phase 312
Response to Dr. Ying Cui comments 277
Thrombotic and Infectious Complications in Patients with Autoimmune Hemolytic Anemia: A Multicenter Observational Study 201
Impact of primary cancer history and molecular landscape in therapy-related myeloid neoplasms 194
Arterial Stiffness as a New Predictor of Clinical Outcome in Patients with Polycythemia Vera 178
Exploring few-shot object detection on blood smear images: a case study of leukocytes and schistocytes 136
VEXAS syndrome: is it more a matter of inflammation or hematopoietic clonality? A case series approach to diagnosis, therapeutic strategies and transplant management 127
Beneath the surface in autoimmune hemolytic anemia: pathogenetic networks, therapeutic advancements and open questions 102
Unravelling a clinical role of peripheral blood leukemia stem cells at diagnosis in chronic myeloid leukemia patients: Final results of prospective FLOWERS study 54
GIMEMA survey on the management of chronic myeloid leukemia patients in the third line and beyond: insights from Italian hematologists 51
The role of satisfaction with care among factors affecting health-related quality of life in people with cancer: a cross-sectional study 47
Health‐related quality of life and symptom profile of patients with BCR::ABL1‐negative myeloproliferative neoplasms: Real‐world evidence from the GIMEMA‐PROPHECY observational study 46
Early Diagnosis of Gaucher Disease and ASMD in Sardinia: the “ICHNOS” Project 32
Totale 351.706
Salva come PNG Salva come JPEG
Categoria #
all - tutte 376.366
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 376.366
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.391 0 0 0 0 0 0 0 0 0 1.043 848 500
2021/20225.564 448 372 235 320 437 382 265 281 533 736 903 652
2022/20237.277 430 861 931 581 539 826 413 599 506 521 712 358
2023/20248.692 389 300 383 540 675 1.558 1.186 666 556 612 866 961
2024/2025298.477 9.454 105.120 175.909 2.949 1.092 1.464 1.375 90 321 188 171 344
2025/20267.698 501 358 638 648 478 462 1.332 352 2.340 589 0 0
Totale 351.706